161 related articles for article (PubMed ID: 33209615)
1. Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib.
Wang Y; He Y; Tian P; Wang W; Wang K; Chuai S; Li Y; Zhao S; Wang Y; Li W
Transl Lung Cancer Res; 2020 Oct; 9(5):1952-1962. PubMed ID: 33209615
[TBL] [Abstract][Full Text] [Related]
2. Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib.
Ding PN; Roberts TL; Chua W; Becker TM; Caixeiro N; de Souza P; Gao B; Lee CK; Itchins M; Westman H; Clarke S; Blinman P; Kao S; John T; Leal JL; Bray VJ
Transl Lung Cancer Res; 2021 Apr; 10(4):1623-1634. PubMed ID: 34012779
[TBL] [Abstract][Full Text] [Related]
3. Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy.
Fu Y; Wang A; Zhou J; Feng W; Shi M; Xu X; Zhao H; Cai L; Feng J; Lv X; Zhang X; Xu W; Zhang Z; Ma G; Wang J; Zhou T; Zhao D; Fang H; Liu Z; Huang JA
Front Oncol; 2021; 11():621992. PubMed ID: 33718183
[TBL] [Abstract][Full Text] [Related]
4. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
[TBL] [Abstract][Full Text] [Related]
5. Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation.
Joshi A; Butle A; Hait S; Mishra R; Trivedi V; Thorat R; Choughule A; Noronha V; Prabhash K; Dutt A
Transl Oncol; 2022 Aug; 22():101461. PubMed ID: 35653897
[TBL] [Abstract][Full Text] [Related]
6.
Zheng Q; Huang Y; Zhao H; Yang Y; Hong S; Hou X; Zhao Y; Ma Y; Zhou T; Zhang Y; Fang W; Zhang L
Transl Lung Cancer Res; 2020 Jun; 9(3):471-483. PubMed ID: 32676311
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P
Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999
[TBL] [Abstract][Full Text] [Related]
8. The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer.
Pan G; Chen K; Yu X; Sheng J; Fan Y
Transl Cancer Res; 2021 Jun; 10(6):2895-2905. PubMed ID: 35116599
[TBL] [Abstract][Full Text] [Related]
9. Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first-line EGFR inhibitor resistance in lung cancer.
Lin YT; Ho CC; Hsu WH; Liao WY; Yang CY; Yu CJ; Tsai TH; Yang JC; Wu SG; Hsu CL; Hsieh MS; Huang YL; Wu CL; Shih JY
Cancer Med; 2023 Dec; 13(1):. PubMed ID: 38140788
[TBL] [Abstract][Full Text] [Related]
10. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
11. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
[TBL] [Abstract][Full Text] [Related]
12. ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib.
Romero A; Serna-Blasco R; Alfaro C; Sánchez-Herrero E; Barquín M; Turpin MC; Chico S; Sanz-Moreno S; Rodrigez-Festa A; Laza-Briviesca R; Cruz-Bermudez A; Calvo V; Royuela A; Provencio M
Transl Lung Cancer Res; 2020 Jun; 9(3):532-540. PubMed ID: 32676317
[TBL] [Abstract][Full Text] [Related]
13. Performance of different methods for detecting T790M mutation in the plasma of patients with advanced NSCLC after developing resistance to first-generation EGFR-TKIs in a real-world clinical setting.
Hou T; Zeng J; Xu H; Su S; Ye J; Li Y
Mol Clin Oncol; 2022 Apr; 16(4):88. PubMed ID: 35251639
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (
Xu Z; Hao X; Wang Q; Wang J; Yang K; Wang S; Teng F; Li J; Xing P
Cancer Manag Res; 2022; 14():863-873. PubMed ID: 35256860
[TBL] [Abstract][Full Text] [Related]
15. The emergence of various genetic alterations mediated the Osimertinib resistance of a patient harboring heterozygous germline EGFR T790M: a case report.
Liu B; Qin J; Yin Y; Zhai L; Liu G; Lizaso A; Shi D
Ann Transl Med; 2021 Jan; 9(1):80. PubMed ID: 33553373
[TBL] [Abstract][Full Text] [Related]
16. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
Santarpia M; Liguori A; Karachaliou N; Gonzalez-Cao M; Daffinà MG; D'Aveni A; Marabello G; Altavilla G; Rosell R
Lung Cancer (Auckl); 2017; 8():109-125. PubMed ID: 28860885
[TBL] [Abstract][Full Text] [Related]
17. Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real-world clinical example.
Wei B; Zhao C; Li J; Zhao J; Ren P; Yang K; Yan C; Sun R; Ma J; Guo Y
Mol Oncol; 2019 May; 13(5):1226-1234. PubMed ID: 30927306
[TBL] [Abstract][Full Text] [Related]
18. EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome.
Vendrell JA; Quantin X; Aussel A; Solassol I; Serre I; Solassol J
Transl Lung Cancer Res; 2021 Nov; 10(11):4084-4094. PubMed ID: 35004240
[TBL] [Abstract][Full Text] [Related]
19. Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.
Zhang YC; Chen ZH; Zhang XC; Xu CR; Yan HH; Xie Z; Chuai SK; Ye JY; Han-Zhang H; Zhang Z; Bai XY; Su J; Gan B; Yang JJ; Li WF; Tang W; Luo FR; Xu X; Wu YL; Zhou Q
EBioMedicine; 2019 May; 43():180-187. PubMed ID: 31027916
[TBL] [Abstract][Full Text] [Related]
20. CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M-positive lung cancer after osimertinib.
Kato R; Hayashi H; Sakai K; Suzuki S; Haratani K; Takahama T; Tanizaki J; Nonagase Y; Tanaka K; Yoshida T; Takeda M; Yonesaka K; Kaneda H; Nishio K; Nakagawa K
Int J Clin Oncol; 2021 Sep; 26(9):1628-1639. PubMed ID: 34117553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
